July 29, 2026 Agilent Technologies Inc. Honors Professor Zongwei Cai with Prestigious Research Catalyst Award Agilent Technologies has awarded the ARC Award to Professor Zongwei Cai for his innovative research on detecting PFAS and environmental contaminants. His work integrates advanced analytical techniques with toxicological models, aiming to improve public health and environmental safety.
July 28, 2026 Agilent Technologies Inc. to Announce Third-Quarter Fiscal Year 2026 Financial Results Agilent Technologies is set to release its Q3 FY 2026 financial results on August 26, followed by a conference call at 1:30 p.m. PDT. Investors are eager for insights into the company's performance and future strategies.
July 23, 2026 Agilent Technologies Secures EU Approval for PD-L1 IHC 22C3 pharmDx in Cancer Diagnostics Agilent Technologies has received EU certification for its PD-L1 IHC 22C3 pharmDx, aiding in the diagnosis of specific cancers and improving treatment decisions. This marks a significant advancement in precision oncology, highlighting collaboration with Merck and the tool's utility across various tumor types.
July 14, 2026 Agilent Technologies Secures FDA Approval for Pivotal Diagnostic Tool Agilent Technologies has secured FDA approval for its PD-L1 IHC 28-8 pharmDx assay, a diagnostic tool aimed at identifying patients with specific cancers eligible for OPDIVO® treatment. This advancement underscores the importance of precision medicine in oncology, particularly for gastric and esophageal cancers, which pose significant health challenges globally.
July 08, 2026 Agilent Technologies Expands Altura Portfolio: A Game Changer for Biotherapeutic Analysis Agilent Technologies has launched new Altura SEC and PLRP-S columns, enhancing biopharmaceutical analytics. These columns support diverse applications, delivering improved sensitivity and reliability for critical workflows in drug development.
July 01, 2026 Agilent Technologies Inc. Unveils AI-Driven Analysis Module for Enhanced Research Capabilities Agilent Technologies has launched the xCELLigence RTCA eSight AI module, integrating AI into cell imaging analysis to enhance efficiency and standardization in biopharma research. This innovation significantly reduces manual efforts and improves the consistency of results, paving the way for faster discoveries.
June 25, 2026 Agilent Technologies Completes Strategic Acquisition of Biocare Medical Agilent Technologies has completed the acquisition of Biocare Medical, significantly enhancing its pathology portfolio and diagnostic capabilities. This strategic move is expected to positively impact Agilent's financial performance and service offerings in the clinical and research sectors.
June 03, 2026 Agilent Technologies Partners with OpenAI and BCG to Transform AI Capabilities Agilent Technologies has teamed up with OpenAI and BCG to boost AI integration across its operations. This collaboration aims to accelerate AI deployment, enhance customer experiences, and foster innovative product development, positioning Agilent as a leader in AI-driven solutions.
June 02, 2026 Agilent Technologies Expands FDA Approval for PD-L1 Testing Across Multiple Cancer Types Agilent Technologies has received FDA approval to expand its PD-L1 IHC 22C3 test, now applicable to several cancer types, including ESCC and TNBC. This advancement supports oncologists in identifying patients for immunotherapy, streamlining testing processes for improved efficiency.
June 01, 2026 Agilent Technologies Inc. Reports Strong Q2 2026 Financial Performance Amid Strategic Growth Initiatives Agilent Technologies Inc. reported a robust Q2 2026, achieving $1.835 billion in revenue—a 10% increase year-over-year. The company also announced its acquisition of Biocare, expected to strengthen its Life Sciences segment. Despite external challenges, Agilent remains focused on innovation and operational efficiency.
May 28, 2026 Agilent Technologies Unveils OpenLab Sync: A Game-Changer for Laboratory Digitalization Agilent Technologies has unveiled OpenLab Sync, a Lab Execution System designed to enhance digital connectivity and compliance in laboratories. This platform integrates with USP MethodConnect and incorporates AI-driven features to streamline workflows, ensuring consistency and efficiency in regulated environments.
May 27, 2026 Agilent Technologies Reports Impressive Q2 2026 Financial Results Agilent Technologies has reported impressive Q2 2026 results, with a 10% revenue increase and significant growth in net income. The company's strong performance across its business segments, coupled with a focus on innovation and operational excellence, positions it well for future success.
May 26, 2026 Agilent Technologies Inc. Unveils Revolutionary Multi-Attribute Method Solution for BioPharma Quality Control Agilent Technologies has launched its Multi-Attribute Method (MAM) solution, designed to streamline quality control in biopharma. This innovative workflow integrates advanced analytical techniques to manage the complexities of biologics, ensuring compliance and efficiency in QC laboratories.
May 26, 2026 Agilent Technologies Unveils New GC Systems to Elevate Laboratory Efficiency Agilent Technologies has launched the 8890B and 8860B gas chromatography systems, featuring GC Assist technology to boost laboratory efficiency and data accuracy. These advancements aim to mitigate downtime and improve performance, supporting scientists in delivering high-quality results.
May 22, 2026 Agilent Technologies Inc. Launches the 9500 ICP-MS: A Game Changer in Trace Element Analysis Agilent Technologies has launched the 9500 ICP-MS, a groundbreaking system designed to improve trace elemental analysis. With advanced features like the Air Cell and AHM, this technology enhances productivity while simplifying complex testing processes for laboratories.
May 21, 2026 Agilent Technologies Unveils Cutting-Edge 1290 Infinity III Fluorescence Detector Agilent Technologies has launched the 1290 Infinity III Fluorescence Detector, a revolutionary tool for ultra-high-performance liquid chromatography. This detector offers ultra-trace sensitivity and is designed to integrate seamlessly into existing lab workflows, enhancing analytical confidence across various applications.
May 20, 2026 Agilent Technologies Inc. Announces Quarterly Cash Dividend Agilent Technologies Inc. has declared a quarterly cash dividend of 25.5 cents per share, payable on July 22, 2026. This move demonstrates the company’s financial strength and ongoing commitment to enhancing shareholder value.
May 20, 2026 Agilent Technologies Partners with NATi to Propel Lipid-Conjugated Oligonucleotide Research Agilent Technologies and Singapore's NATi have launched a two-year collaboration to advance lipid-conjugated oligonucleotide research, enhancing therapeutic delivery beyond the liver. This partnership aims to address analytical challenges and improve preclinical development in the growing oligonucleotide therapeutics market.
May 04, 2026 Agilent Technologies Announces New Chief Legal Officer: Michael Buckner Takes Charge Agilent Technologies has appointed Michael Buckner as Chief Legal Officer, effective immediately. With nearly 30 years of experience, Buckner's leadership will strengthen Agilent's legal governance as the company expands globally in analytical and clinical technologies.
April 28, 2026 Agilent Technologies Set to Reveal Q2 Fiscal Year 2026 Financial Results Agilent Technologies is set to announce its Q2 FY26 financial results on May 27, 2026. The company will hold a conference call to discuss the results and future strategies, important for investors and analysts monitoring market conditions.
April 15, 2026 Agilent Technologies Inc. Showcases Cutting-Edge Cancer Research Solutions at AACR 2026 Agilent Technologies will showcase innovative cancer research solutions at AACR 2026, including the BioTek Cytation 9 and AI-enabled software for live-cell imaging. Engaging educational sessions and strategic collaborations highlight Agilent's commitment to advancing cancer diagnostics.
April 01, 2026 Agilent Technologies Unveils BioTek Cytation 9 Cell Imaging Multimode Reader Agilent Technologies has launched the BioTek Cytation 9, a multimode cell imaging reader designed to improve laboratory workflows and enhance research productivity. Featuring advanced imaging capabilities and integrated functionalities, it addresses the needs of modern researchers in pharmaceutical and biotechnology labs.
March 26, 2026 Agilent Technologies Secures FDA Approval for Revolutionary Diagnostic in Cancer Treatment Agilent Technologies has secured FDA approval for its PD-L1 IHC 22C3 pharmDx, aiding in the identification of esophageal and GEJ carcinoma patients for KEYTRUDA treatment. This milestone enhances precision medicine and expands the test's applications across multiple cancer types.
March 19, 2026 Agilent Technologies Inc. Showcases Innovation in Precision Oncology and Digital Pathology at USCAP 2026 Agilent Technologies will showcase its innovations in precision oncology and digital pathology at USCAP 2026, introducing new biomarker testing capabilities and improved digital workflows. With a focus on collaboration and education, Agilent aims to lead the transformation toward integrated pathology solutions.
March 11, 2026 Agilent Technologies Unveils Agilent Advanced Therapeutics: A Unified CDMO Solution Agilent Technologies has launched Agilent Advanced Therapeutics, a new CDMO solution that integrates manufacturing capabilities across North America. This initiative aims to offer a comprehensive suite of customizable services to enhance drug development processes, supporting clients in creating life-changing therapies.
March 09, 2026 Agilent Technologies to Acquire Biocare Medical: A Strategic Move to Enhance Pathology Solutions Agilent Technologies is set to acquire Biocare Medical for $950 million, enhancing its pathology portfolio with Biocare's leading IHC solutions. This strategic move aims to drive growth, innovation, and improved patient outcomes in the healthcare landscape.
March 03, 2026 Agilent Technologies Inc. Reports Q1 2026 Financial Results: Revenue Growth Amidst Operational Challenges Agilent Technologies Inc. reported a 7% revenue growth in Q1 2026, reaching $1,798 million, despite facing operational challenges and a decline in net income to $305 million. The Life Sciences segment led growth, while increased costs and tariffs impacted profitability.
February 25, 2026 Agilent Technologies Inc. Reports Strong First-Quarter Financial Results for Fiscal Year 2026 Agilent Technologies, Inc. reported a revenue of $1.80 billion for Q1 2026, marking a 7% increase year-over-year. Despite a slight dip in GAAP net income, the company maintains a strong outlook with solid performances across its segments.
February 23, 2026 Agilent Technologies Inc. to Speak at TD Cowen’s 46th Annual Health Care Conference Agilent Technologies will participate in TD Cowen's 46th Annual Health Care Conference on March 3, 2026, featuring a fireside chat with its CFO and Head of Investor Relations. The event highlights Agilent's commitment to transparency and investor engagement, along with the opportunity to access a live webcast of the presentation.
February 11, 2026 Agilent Technologies Declares Quarterly Dividend of 25.5 Cents per Share Agilent Technologies Inc. has declared a quarterly dividend of 25.5 cents per share, payable on April 22, 2026. This announcement underscores Agilent's solid financial performance and commitment to shareholder returns, while future dividends will be determined by the board.
February 11, 2026 Agilent Technologies Secures FDA Approval for PD-L1 IHC 22C3 pharmDx in EOC Treatment Agilent Technologies has secured FDA approval for PD-L1 IHC 22C3 pharmDx, a diagnostic tool that identifies ovarian cancer patients suitable for KEYTRUDA treatment. This marks a significant advancement in precision oncology, potentially improving patient outcomes.
February 04, 2026 Agilent Technologies Unveils Cutting-Edge Automation Solutions at SLAS2026 Agilent Technologies will unveil cutting-edge automation solutions at SLAS2026, focusing on enhanced lab efficiencies through AI, robotics, and compliance-ready software. Attendees can expect live demos and insights into the future of automated laboratories.
February 02, 2026 Agilent Technologies Set to Release First-Quarter Financial Results for FY 2026 Agilent Technologies is set to release its first-quarter financial results for FY 2026 on February 25. The accompanying conference call will provide insights into the company’s performance and strategic initiatives, crucial for investors and analysts.
January 23, 2026 Agilent Technologies Launches Agilent S540MD Slide Scanner System: A Leap Forward in Digital Pathology Agilent Technologies has launched the S540MD Slide Scanner System to improve workflow efficiency in pathology laboratories. Featuring automated scanning modes and AI-assisted tissue detection, this system addresses the growing demands of modern pathology. Initially available in select European markets, it represents a significant step in advancing digital pathology.
December 22, 2025 Agilent Technologies Inc. Reports Strong Financial Performance in 2025 Agilent Technologies Inc. showed significant financial growth in 2025, with a net revenue of $6.948 billion, a 7% increase from the previous year. The company attributed this success to strategic acquisitions and strong performance in key market segments, particularly Life Sciences and Diagnostics.
December 16, 2025 Agilent Technologies Set to Showcase Innovations at J.P. Morgan Healthcare Conference Agilent Technologies is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, showcasing their latest innovations and financial achievements. With a revenue of $6.95 billion in fiscal 2025, Agilent reinforces its commitment to advancing laboratory technologies and improving healthcare outcomes.
December 05, 2025 Agilent Technologies and Monash University Malaysia Collaborate to Enhance Biotech Innovation Agilent Technologies and Monash University Malaysia have renewed their partnership with the launch of the MUMPMP-Agilent BioDiscovery Hub, aimed at advancing biotechnology research. This collaboration will provide state-of-the-art equipment and training, enhancing research capabilities in fields like biomedical science and pharmaceuticals.
December 01, 2025 Agilent Technologies Unveils 21 CFR Part 11 Compliance Software for xCELLigence RTCA eSight Agilent Technologies has introduced 21 CFR Part 11 compliance software for its xCELLigence RTCA eSight system, enhancing regulatory compliance in biopharmaceuticals. The software offers robust security features and is designed to streamline audits and regulatory submissions, supporting drug development from discovery to manufacturing.
November 24, 2025 Agilent Technologies Inc Reports Strong Fourth-Quarter Fiscal Year 2025 Results Agilent Technologies, Inc. reported robust Q4 2025 results with $1.86 billion in revenue and $434 million in net income, reflecting strong growth in life sciences and diagnostics. The company projects continued growth for FY26, driven by strategic innovation and customer engagement.
November 19, 2025 Agilent Technologies Inc. Declares Quarterly Cash Dividend Agilent Technologies Inc. has declared a quarterly cash dividend of 25.5 cents per share, payable on January 28, 2026. This decision reflects the company's commitment to rewarding shareholders amid robust financial performance, with $6.51 billion in revenue for fiscal year 2024.
November 18, 2025 Agilent Technologies to Engage Investors at Citi's 2025 Global Healthcare Conference Agilent Technologies will participate in Citi's 2025 Global Healthcare Conference, offering insights into its strategic direction and innovations in healthcare. The event will feature a live webcast, ensuring broad accessibility for investors.
November 13, 2025 Agilent Technologies Partners with National Heart Centre Singapore to Tackle Metabolic Heart Failure Agilent Technologies has formed a five-year partnership with the National Heart Centre Singapore to advance research on metabolic heart failure. Leveraging advanced analytics and clinical expertise, the collaboration aims to develop new therapies and improve patient care in this critical area of cardiovascular medicine.
November 12, 2025 Agilent Technologies Awards UC Davis Research Catalyst Grant for Innovative Peptide Therapeutics Agilent Technologies has awarded UC Davis a grant to support Professor Marie Heffern's innovative research on peptide therapeutics for diabetes and obesity. The study will explore metal-peptide interactions to improve drug formulation and efficacy. This initiative highlights a significant advancement in addressing critical challenges in pharmaceutical development.
November 11, 2025 Agilent Technologies and University of Melbourne Launch Innovation Hub to Tackle Environmental Challenges Agilent Technologies and the University of Melbourne have launched the Agilent Innovation Hub to address environmental health issues. The hub will focus on identifying emerging pollutants using cutting-edge technology, fostering collaboration between academia and industry to enhance population health in Australia.
October 30, 2025 Agilent Technologies Inc. Set to Release Fourth-Quarter Financial Results Agilent Technologies Inc. is set to announce its fourth-quarter financial results on November 24, 2025, followed by a conference call for stakeholders. Analysts are eager to see key metrics like revenue growth and EPS, reflecting Agilent's commitment to innovation and market leadership.
October 27, 2025 Agilent Technologies Inc. Appoints Adam S. Elinoff as Chief Financial Officer Agilent Technologies has appointed Adam S. Elinoff as Chief Financial Officer, effective November 17, 2025. With 19 years at Amgen, Elinoff's leadership is poised to enhance Agilent's financial operations and strategic planning, furthering the company's innovative growth.
September 30, 2025 Agilent Technologies Expands Airport Security Solutions with New Insight Series Agilent Technologies has launched the Insight Series Alarm Resolution Systems, featuring advanced liquid explosive detection systems to improve airport security. With low false alarm rates and rapid scanning, these systems promise to enhance safety and adapt to evolving regulations, positioning Agilent as a leader in airport security innovation.
September 29, 2025 Agilent Technologies Unveils Altura Line of Inert HPLC Columns for Enhanced Biotherapeutic Testing Agilent Technologies has introduced the Altura Ultra Inert HPLC columns, designed for biotherapeutics applications. These columns enhance sensitivity and performance, crucial for meeting stringent regulatory demands in drug development. Industry feedback highlights significant improvements in analytical capabilities and efficiency.
August 29, 2025 Agilent Technologies Inc. Reports Robust Q3 2025 Results Amidst Strategic Restructuring Agilent Technologies Inc. reported a robust 10% revenue increase in Q3 2025, driven by strong performance across all segments. Despite facing global economic challenges, the company’s strategic restructuring is set to enhance operational efficiency and customer experience.
July 28, 2025 Agilent Technologies Strengthens Environmental Research Collaboration in Singapore Agilent Technologies has partnered with Nanyang Technological University’s NEWRI to advance water contaminant research in Singapore. This collaboration will leverage Agilent's advanced technologies to improve detection methods for emerging contaminants, including microplastics, over the next three years.
June 02, 2025 Agilent Technologies Inc. Reports 2025 Q2 Financial Results: A Mixed Bag Amidst Strategic Changes Agilent Technologies Inc. reported a 6% revenue increase for Q2 2025, driven by its Life Sciences and Diagnostics Markets segment. However, net income fell to $215 million due to rising operational costs and external market challenges. The company is focused on enhancing customer experience amid ongoing restructuring efforts.
May 15, 2025 Agilent Technologies Inc. to Showcase Leadership at Jefferies Global Healthcare Conference Agilent Technologies Inc. will participate in the Jefferies Global Healthcare Conference on June 4, 2025. CEO Padraig McDonnell and CFO Bob McMahon will discuss the company's strategic vision and financial outlook, with a live webcast available for stakeholders.
May 08, 2025 Crawford & Company Declares Quarterly Dividends Amid Steady Growth Crawford & Company announced a quarterly dividend of $0.07 per share for both Class A and Class B stocks, reinforcing its commitment to shareholder value. The company showcases solid financial standing and operational efficiency, making it an attractive investment option.
May 05, 2025 Crawford & Company Reports Strong First Quarter Results for 2025 Crawford & Company reported impressive first quarter results for 2025, with revenues increasing by 3% to $312 million and net income surging by 139% to $6.7 million. The company demonstrated operational efficiency and growth across all segments, positioning itself for continued success.
May 01, 2025 Agilent Technologies Unveils Revolutionary Seahorse XF Flex Analyzer for 3D Tissue Research Agilent Technologies has unveiled the Seahorse XF Flex Analyzer, a 24-well system designed for real-time metabolic analysis of complex 3D tissues. This innovative tool enhances research capabilities and offers deeper insights into metabolism, crucial for understanding diseases and developing therapies.
April 24, 2025 Agilent Technologies Inc. Unveils Groundbreaking Innovations in Cancer Research at AACR 2025 Agilent Technologies is set to unveil innovative products and strategic partnerships at the AACR 2025 Annual Meeting, aimed at transforming cancer research and diagnostics. Highlights include advanced DNA panels, multiomics assays, and collaborations with industry leaders to improve patient outcomes.
April 22, 2025 Crawford & Company® Prepares for First Quarter 2025 Earnings Release Crawford & Company is set to release its Q1 2025 earnings on May 5, 2025, followed by a conference call on May 6. Investors can participate via audio or webcast to gain insights into the company's performance and strategic developments.
April 17, 2025 Agilent Technologies Secures European IVDR Certification for Pivotal Companion Diagnostic Assay Agilent Technologies has received IVDR certification for its PD-L1 IHC 22C3 pharmDx assay, crucial for identifying gastric cancer patients eligible for KEYTRUDA treatment. This certification expands the assay's application to several cancer types, promising to improve diagnostic accuracy and patient outcomes across Europe.
April 16, 2025 Agilent Technologies to Unveil Second-Quarter Financial Results on May 28, 2025 Agilent Technologies will release its Q2 2025 financial results on May 28, 2025, after market close, followed by a conference call. Investors anticipate insights into the company's performance and strategic direction.
March 10, 2025 Agilent Technologies Expands Diagnostic Capabilities with New EU Certification Agilent Technologies has received EU IVDR certification for its PD-L1 IHC 28-8 pharmDx kit, expanding its diagnostic capabilities for lung cancer and melanoma. This certification allows for two new treatment indications, improving patient access to critical therapies and enhancing collaboration between pathologists and oncologists.
March 03, 2025 Agilent Technologies Inc. Reports Mixed Financial Results for Q1 2025 Agilent Technologies Inc. reported a 1% revenue increase to $1.681 billion in Q1 2025, despite challenges in specific markets. While the Life Sciences segment thrived, overall net income fell by 8%. The company emphasizes innovation and sustainability amid ongoing economic pressures.
March 03, 2025 Crawford & Company Reports Fourth Quarter and Full Year Results for 2024 Crawford & Company announced significant growth for Q4 and full year 2024, with revenues climbing 17% and a turnaround in net income. The CEO highlighted operational excellence and strategic growth as key focuses for the future.
February 27, 2025 Agilent Technologies Set to Shine at TD Cowen Health Care Conference Agilent Technologies will participate in the TD Cowen Health Care Conference on March 4, 2025, featuring a discussion with CEO Padraig McDonnell. The event highlights Agilent's strategic initiatives and market leadership in health care, with a live webcast available for interested stakeholders.
February 26, 2025 Agilent Technologies Reports First-Quarter Financial Results for Fiscal Year 2025 Agilent Technologies reported Q1 2025 revenues of $1.68 billion, reflecting modest growth. Despite a decrease in net income, the company maintains a positive outlook for the year.
February 19, 2025 Agilent Technologies Announces Quarterly Cash Dividend Agilent Technologies has declared a quarterly cash dividend of 24.8 cents per share, reinforcing its commitment to shareholder value. This announcement reflects the company's solid financial position and ongoing growth within the laboratory technology sector.
February 18, 2025 Crawford & Company Announces Fourth Quarter and Full Year 2024 Earnings Conference Call Crawford & Company will announce its Q4 and full year 2024 earnings on March 3, 2025, followed by a conference call on March 4. Stakeholders can access financial information via the company’s investor website.
February 07, 2025 Crawford & Company Declares Quarterly Dividends Amid Steady Growth Crawford & Company has declared a quarterly dividend of $0.07 per share for both Class A and B stocks, payable on March 7, 2025. This decision highlights the company's strong financial performance and commitment to returning value to shareholders while investing in growth.
January 24, 2025 SWOT Analysis of Agilent Technologies Inc. in 2025 This SWOT analysis assesses Agilent Technologies Inc. in 2025, detailing its strengths in market leadership and innovation, weaknesses like dependency on economic conditions, and opportunities in emerging markets. The company must navigate competitive threats and regulatory challenges to maintain its industry position.
December 20, 2024 Agilent Technologies Inc. Reports 2024 Annual Results: A Year of Challenges and Strategic Growth Agilent Technologies' 2024 annual report reveals a 5% decline in net revenue to $6.51 billion, though net income rose to $1.29 billion. The company faces market challenges while pursuing strategic growth through acquisitions and innovation.
August 30, 2024 Agilent Technologies Inc. Reports Q3 2024 Financial Results: A Mixed Bag of Performance Agilent Technologies' Q3 2024 financial results show a 6% decrease in revenue to $1.57 billion, yet net income surged to $282 million. The performance varied across segments, with declines in Life Sciences and Diagnostics, but growth in Agilent CrossLab. Strategic acquisitions and cost management efforts are crucial as the company aims for sustainable growth.
June 03, 2024 Agilent Technologies Inc. Reports Mixed Results in 2024 Q2 Agilent Technologies Inc. reported mixed financial results for Q2 2024, with an 8% decrease in net revenue but a slight increase in net income. The company faces challenges in several segments, prompting strategic cost management and a focus on innovation and sustainability for future growth.
